OncoSignal
Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Colorectal cancer

MSI-H immunotherapy, BRAF V600E, HER2 and KRAS G12C combinations.

Live from ClinicalTrials.gov and PubMed, fetched 2026-11-11 15:10 UTC. Every row links to its source record.

Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:26 UTC.

Phase advances
11
since 2026-07-14
New Ph2+ trials
20
Results posted
5
Readouts due
20
primary completion reached
Trial papers
40
PubMed, last 60 days
  1. Paper
    Spatial Acid-Associated Niches Inform Irinotecan-Based DEB-TACE in Colorectal Liver Metastases: A Multicentre Randomized Trial.

    Weng S, Hu W, Tu J et al. Liver international : official journal of the International Association for the Study of the Liver.

    Publisher pageReports NCT06021015
  2. New trial
    New Ph2 trial: NCT07927998

    Memorial Sloan Kettering Cancer Center. A Study of Retifanlimab After Chemoradiation in People With Anal Cancer

  3. Paper
  4. New trial
    New Ph2/Ph3 trial: NCT07927075

    Sir Run Run Shaw Hospital. Evaluating the Efficacy of Chidamide in Advanced Refractory Colorectal Cancer With High SULF1 Expression

  5. New trial
    New Ph2 trial: NCT07926477

    Second Affiliated Hospital, Zhejiang University, School of Medicine. Trastuzumab Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated mCRC With HER2 Low/Moderate Expression or HER2 Positivity With RAS/BRAF Mutation

  6. New trial
    New Ph2/Ph3 trial: NCT07927049

    Sir Run Run Shaw Hospital. Evaluating the Efficacy of Chidamide in the Treatment of Initial Unresectable Metastatic Colorectal Cancer With High Expression of SULF1

  7. Paper
  8. Results posted
    Results posted: NCT03929666

    A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

  9. New trial
    New Ph2 trial: LEGEND (NCT07917104)

    Fudan University. Circulating Tumor DNA Methylation-Guided Adjuvant Therapy Decision-Making in Patients With Resectable Colorectal Cancer Liver Metastases After Resection

  10. New trial
    New Ph1/Ph2 trial: A Phase Ib/II (NCT07915921)

    Genfleet Therapeutics (Shanghai) Inc.. A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer

  11. New trial
    New Ph3 trial: NCT07913360

    Genfleet Therapeutics (Shanghai) Inc.. GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer

  12. New trial
    New Ph2 trial: ACE-Dose-CRC (NCT07913906)

    University of Calgary. Alberta Cancer Exercise Dose in Colorectal Cancer

  13. Paper
  14. Readout due
    Readout due: NCT05752136 reached primary completion

    Sir Run Run Shaw Hospital. Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma

  15. Paper
  16. Paper
  17. Paper
  18. Readout due
    Readout due: NCT03796884 reached primary completion

    Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer

  19. Readout due
    Readout due: NCT04486378 reached primary completion

    BioNTech SE. A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

  20. Readout due
    Readout due: ASIST reached primary completion

    Bexion Pharmaceuticals, Inc.. BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

  21. Readout due
    Readout due: NCT02008656 reached primary completion

    Memorial Sloan Kettering Cancer Center. Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

  22. Results posted
    Results posted: RSCAMPTO (NCT01220063)

    Radiosensitizing Chemotherapy withSBRT for the Treatment of Inoperable Liver and/or Lung Metastases of CRC

  23. Results posted
    Results posted: NCT00200200

    Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer

  24. Phase advance
    Immunotherapy advances to Ph2 (indication level)

    West China Hospital posted PRIM-CRC3: Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer

  25. New trial
    New Ph2 trial: PRIM-CRC3 (NCT07904130)

    West China Hospital. Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer

  26. New trial
    New Ph1 trial: NCT07903857

    Guizhou Sinorda Pharmaceutical Co., Ltd.. SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors

  27. New trial
    New Ph3 trial: mRCATS (NCT07900061)

    Sir Run Run Shaw Hospital. Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer

  28. New trial
    New Ph1/Ph2 trial: NCT07900165

    CytomX Therapeutics. Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer

  29. New trial
    New Ph2 trial: NCT07896681

    Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study

  30. New trial
    New Ph2 trial: NCT07895355

    RemeGen Co., Ltd.. Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer

  31. New trial
    New Ph2 trial: NCT07896096

    Renmin Hospital of Wuhan University. Ivarmacitinib Combined With Camrelizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment

  32. Paper
  33. Results posted
    Results posted: NCT04230499

    Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

  34. New trial
    New Ph2 trial: TRIP-FAST (NCT07888309)

    Ruijin Hospital. SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer

  35. New trial
    New Ph3 trial: NCT07885384

    West China Hospital. Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With Liver-Only Metastatic Colorectal Cancer

  36. New trial
    New Ph2 trial: NCT07884188

    Fudan University. Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer

  37. Results posted
    Results posted: AUDREY (NCT05589597)

    EO4010 in Previously Treated Metastatic Colorectal Carcinoma

  38. Paper
  39. Phase advance
    Serplulimab advances to Ph3 (indication level)

    Fudan University posted TORCH-C2: Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS

  40. New trial
    New Ph3 trial: TORCH-C2 (NCT07877597)

    Fudan University. Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS

  41. New trial
    New Ph1 trial: NCT07878988

    LTZ Therapeutics, Inc.. This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

  42. Readout due
    Readout due: NCT04868877 reached primary completion

    Merus B.V.. Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  43. Readout due
    Readout due: NCT07213570 reached primary completion

    National Cancer Institute, Naples. STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

  44. Readout due
    Readout due: NCT05985109 reached primary completion

    Peking University Cancer Hospital & Institute. KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

  45. Readout due
    Readout due: NCT07235293 reached primary completion

    Kahr Bio Australia Pty Ltd. A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

  46. Readout due
    Readout due: KontRASt-03 reached primary completion

    Novartis Pharmaceuticals. Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

  47. Paper
  48. Paper
  49. Paper
  50. Readout due
    Readout due: NCT04246684 reached primary completion

    Prof. Dr. med. Claus Rödel. Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients

  51. Paper
    The yield of artificial intelligence (GI genius) in Lynch syndrome -A randomized tandem-colonoscopy trial.

    Ido L, Shomron BH, Idan L et al. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

    Publisher page
  52. Paper
  53. Phase advance
    VVD-133214 advances to Ph2 (indication level)

    Vividion Therapeutics, Inc. posted NCT07811193: A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

  54. Readout due
    Readout due: NCT06730750 reached primary completion

    Bristol-Myers Squibb. A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

  55. Readout due
    Readout due: NCT07720115 reached primary completion

    M.D. Anderson Cancer Center. Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer

  56. Readout due
    Readout due: METEORITE reached primary completion

    Brown University. Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

  57. Readout due
    Readout due: EXCALIBUR1+2 reached primary completion

    Oslo University Hospital. HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.

  58. Readout due
    Readout due: MRD-GI reached primary completion

    Georgetown University. Evaluating Novel Therapies in ctDNA Positive GI Cancers

  59. Phase advance
    Cetuximab advances to Ph3 in Relapsed or refractory (segment level)

    Genmab posted NCT07775287: Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

  60. Phase advance
    Leucovorin (Calcium Folinate) advances to Ph3 in Relapsed or refractory (segment level)

    Genmab posted NCT07775287: Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

  61. Phase advance
    Oxaliplatin advances to Ph3 in Relapsed or refractory (segment level)

    Genmab posted NCT07775287: Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

  62. Phase advance
    Irinotecan advances to Ph3 in Relapsed or refractory (segment level)

    Genmab posted NCT07775287: Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

  63. Readout due
    Readout due: NCT06862115 reached primary completion

    Kasr El Aini Hospital. The Effect of Discontinuation of Renin Angiotensin System Inhibitors on the Perioperative Myocardial Injury in Adult Patients Undergoing Colorectal Cancer Surgery

  64. Phase advance
    Dostarlimab advances to Ph3 (indication level)

    GlaxoSmithKline posted DuraSTAR: A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer

  65. Readout due
    Readout due: MEND-IT reached primary completion

    Catharina Ziekenhuis Eindhoven. Induction Chemotherapy for Locally Advanced Rectal Cancer

  66. Readout due
    Readout due: NCT04495088 reached primary completion

    Ralf Hofheinz. Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

  67. Phase advance
    MRG007 advances to Ph1/Ph2 (indication level)

    Lepu Biopharma Co., Ltd. posted NCT07737600: A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer

  68. Phase advance
    Fruquintinib advances to Ph3 (indication level)

    Sichuan Baili Pharmaceutical Co., Ltd. posted NCT07730489: A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan

  69. Readout due
    Readout due: NCT06484153 reached primary completion

    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

  70. Phase advance
    mFOLFOX6 advances to Ph3 (indication level)

    Genmab posted NCT07702032: Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

  71. Paper

A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.